Meta-analysis results for all treatments

Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method

Treament Trials      
Demonstrated or suggested benefit Inconclusive results Uncertain results Safety results
A EFFACER BBV152 (Bharat Biotech, India)0- - - -
A EFFACER Janssen Ad.26.COV2.S vaccine (JNJ-78436725)0- - - -
A EFFACER_ Vero cell0- - - -
A EFFACER_sequential Immunization0- - - -
BCG vaccination0- - - -
complete primary vaccine series0- - - -
CoVLP (MT-2766, Medicago)0- - - -
DNA vaccine0- - - -
ebola vaccine0- - - -
first booster dose0- - - -
heterologous prime-boost0- - - -
Inactivated virus vaccine0- - - -
mRNA vaccine0- - - -
Non replicating viral vector0- - - -
protein subunit vaccine0- - - -
Replicating Viral Vector0- - - -
seasonal influenza vaccines0- - - -
second booster dose0- - - -
virus-like particles vaccine0- - - -